A practical reference on certificate of analysis: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
This page was last updated on 2026-07-30 and is reviewed periodically as new material appears.
Within the research literature, the peptide is discussed through several provisional mechanisms, including cytoprotection, modulation of growth factor signaling, and interaction with the nitric oxide system. None of these mechanisms is fully characterized, and no single pathway is universally accepted. Review articles typically note the gap between consistent animal findings and sparse human evidence. The compound is classified as a research chemical rather than an approved pharmaceutical, which shapes how studies are designed, funded, and reported.
BPC-157 is a synthetic pentadecapeptide with the sequence GEPPPGKPADDAGLV, corresponding to a partial fragment of a larger protein detected in human gastric juice. The name derives from the parent protein designation BPC, an abbreviation of body protection compound, with 157 acting as a fraction or batch identifier used by the original investigators. Its molecular weight is approximately 1419 daltons, and the chain contains no unusual residues or disulfide bridges. In the literature it is described as a short, water-soluble fragment rather than a complete natural protein.
Identity and purity are usually assessed by reversed-phase high-performance liquid chromatography with ultraviolet detection near 214 nanometers, a wavelength that captures the peptide backbone. The main peak area is reported as a percentage of total peak area, which serves as a conventional purity figure. Mass spectrometry provides an independent check on molecular mass and helps confirm the expected sequence. Additional tests may include amino acid analysis and water content determination. Results are only comparable when the same column, gradient, and detection settings are used.
Peptides are susceptible to hydrolysis, oxidation, and aggregation, and BPC-157 is no exception. The lyophilized powder form is generally more stable than a solution because residual moisture is low and molecular mobility is reduced. Once dissolved, the peptide is exposed to water, oxygen, and trace metal ions that accelerate degradation. Light exposure and repeated freeze-thaw cycles are also commonly cited as sources of loss. These general principles guide most handling recommendations found in supplier documentation.
Standard practice for the solid form is storage at minus twenty degrees Celsius or colder, kept dry and away from light. Containers are usually sealed with a desiccant to limit moisture uptake. Reconstituted solutions are typically held at two to eight degrees Celsius and used within a short window, because potency can decline over days to weeks depending on the buffer and concentration. Freezing an already dissolved sample may help, though repeated thawing is discouraged. Specific shelf-life claims vary between suppliers and are rarely supported by published stability studies.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C62H98N16O22 | computed for the free peptide |
| Molecular weight | about 1419 Da | monoisotopic mass near 1418.7 |
| Amino acid count | 15 | single chain, no disulfide bonds |
| Solubility | freely soluble in water | also dissolves in saline and phosphate buffer |
| Common synonyms | pentadecapeptide BPC, BPC 157 | fragment notation varies by source |
Doses in the literature are usually expressed in micrograms or nanograms per kilogram of body weight. Investigators have administered the peptide by several routes, including injection and oral delivery, depending on the question asked. Route and dose vary widely across studies, which complicates direct comparison of results. Many papers report effects at low doses, but the absence of a standardized protocol limits generalization. Reporting practice differs between research groups.
Some properties, such as the peptide's sequence and molecular mass, are firmly established. Other claims, particularly about mechanism and clinical benefit, remain open questions. Proposed mechanisms include effects on nitric oxide signaling and on cell migration, but these are hypotheses supported by limited evidence. Reviewers often note that the field lacks large controlled human trials. Positive animal findings are best treated as signals for further study rather than as settled conclusions.
Most published studies examine BPC-157 in animal models rather than in humans. Common subjects include rats and mice, and researchers often use models of tissue injury, surgery, or induced inflammation. Reported endpoints include healing rates, blood vessel formation, and markers of tissue repair. These designs provide controlled comparisons, but findings in animals do not automatically transfer to people. Human clinical data remain limited and are frequently described as preliminary.
Lyophilized peptide powder is generally stored at minus twenty degrees Celsius or lower and kept away from light and moisture. Under these conditions degradation is slow, and sealed vials remain stable for extended periods. Once dissolved, the material is less stable, particularly in aqueous buffers near neutral pH, where hydrolysis and oxidation proceed faster. Solutions are usually kept cold and used within days to weeks. Repeated freeze-thaw cycles are avoided because they encourage aggregation.
Identity and purity are established using reversed-phase high-performance liquid chromatography, which separates the peptide from related impurities and yields a percentage purity. Mass spectrometry, typically with electrospray ionization, confirms the molecular mass against the expected value. Amino acid analysis or peptide mapping provides additional sequence confirmation. These methods are complementary, since chromatography measures how much material is present while mass spectrometry verifies what that material is. A certificate of analysis normally reports both.
BPC-157 is a synthetic peptide composed of fifteen amino acid residues, with the sequence Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val. Its name derives from body protection compound, a term used for a protein fraction identified in human gastric juice. Researchers in Zagreb first reported the pentadecapeptide in the early 1990s and described it as a stable fragment of that larger protein. The compound is also catalogued as PL 14736 and, in some commercial contexts, as bepecin. Its molecular formula is C62H98N16O22 and its monoisotopic mass is approximately 1419 daltons.
Most published work on BPC-157 consists of preclinical studies, including rodent models of tissue injury, gastrointestinal lesions, and vascular or tendon damage, together with in vitro cell assays. Reviews frequently note that the mechanisms proposed in these papers remain incompletely characterised and that findings have not been confirmed in large randomised human trials. The compound is widely sold as a research chemical rather than a licensed medicine, and labels commonly carry a statement that it is not for human use. Whether any of the reported animal effects translate to humans is an open question rather than an established result.
Terminology in the literature is not fully standardised. Papers and product listings use BPC-157, BPC 157, and the longer phrase stable gastric pentadecapeptide BPC 157 interchangeably, and synonyms such as bepecin or PL 14736 appear in older or company-linked publications. Purity claims and reported masses can also differ between sources because peptide preparations may include counterions, residual solvents, or bound water. This variability complicates direct comparison of results across studies and makes the exact identity and grade of a given sample worth verifying. Discussions of the compound should therefore specify the source, salt form, and stated purity where those are known.
The antibody, together with the captured target peptide, is then separated from the complex sample digest, after which the highly purified peptide is eluted from the antibody and delivered to a mass spectrometer for measurement. The capture step has been implemented using antibodies bound to magnetic beads as well as antibodies immobilized on flow-through columns. Addition of this specific capture step provides two primary advantages in comparison with a conventional workflow analyzing an unfractionated sample digest: sensitivity and throughput. The antibody can be used to capture the target peptide (and SIS) from a much larger mass of sample than could be analyzed directly by MS, thus allowing lower concentrations to be measured. In practice, assay sensitivity can be improved by 1,000-10,000-fold by this approach. By removing the unbound (non-target) peptides present in the sample digest, the sample presented to the mass spectrometer is drastically simplified, thus reducing the need for peptide separation by liquid chromatography prior to MS analysis. In some cases liquid chromatography has been eliminated entirely, resulting in MS cycle times of 7-20 sec rather than 5–40 minutes required in typical unfractionated digest protocols involving extensive chromatographic separation. By virtue of the extreme specificity of mass spectrometric detection, SISCAPA assays can be combined into multiplex panels without cross-assay interference. Panels combining 22, 50, and 150 assays into a single operation have been demonstrated.
=== Semen displacement === The shape of the human penis is thought to have evolved as a result of sperm competition. Semen displacement is an adaptation of the shape of the penis to draw foreign semen away from the cervix. This means that a male can displace a rival male's sperm from the female reproductive tract before replacing it with his own. Semen displacement has two main benefits for a male. Firstly, by displacing a rival male's sperm, the risk of the rival sperm fertilising the egg is reduced. Secondly, the male replaces the rival's sperm with his own, thereby increasing the probability of his fertilising the egg and successfully reproducing with the female. However, males have to ensure they do not displace their own sperm. It is thought that the relatively quick loss of erection after ejaculation, penile hypersensitivity following ejaculation, and the shallower, slower thrusting of the male after ejaculation prevent this from occurring. The coronal ridge is the part of the human penis thought to have evolved to allow for semen displacement. Research has studied how much semen is displaced by differently shaped artificial genitals. This research showed that, when combined with thrusting, the coronal ridge of the penis is able to remove the seminal fluid of a rival male from within the female reproductive tract. It does this by forcing the semen under the frenulum of the coronal ridge, causing it to collect behind the coronal ridge shaft.
== Personal life == High is married to George Steele, an internist who was on the faculty of the University of Pennsylvania School of Medicine. She has three children, one of whom is actress Sarah Steele.
Fripp intended to create the sound of a "rock gamelan", with an interlocking rhythmic quality to the paired guitars that he found similar to Indonesian gamelan ensembles. In 1981, King Crimson recorded Discipline in London with producer Rhett Davies, who had previously worked with Belew on Talking Heads' Remain in Light and with Fripp on Eno's Another Green World and Before and After Science. The album displayed a very different version of the band, with newer influences including post-punk, new wave, funk, minimalism, pointillism, world music and African percussion, and a sound described in The New Rolling Stone Album Guide as having a "jaw-dropping technique" of "knottily rhythmic, harmonically demanding workouts". The title track was described as a postminimalist rock song. Fripp concentrated on playing complex picked arpeggios, while Belew provided an arsenal of guitar sounds that "often mimic animal noises"; both also experimented with guitar synthesisers. In addition to bass guitar, Levin used the Chapman Stick, a ten-string hybrid guitar and bass instrument played by two-handed tapping, in an "utterly original style". Bruford experimented with Simmons SDSV electronic drums and largely eschewed cymbals. The band's songs were shorter in comparison to previous King Crimson albums, shaped by Belew's pop sensibilities and quirky approach to writing lyrics.
In road transport, the Emission Performance Regulation 2019 says manufacturers of "new passenger cars" should not allow emissions to exceed 95 grams of CO2 per kilometre, and 147 grams of CO2 per kilometre for new light commercial vehicles, but this is merely an "EU fleet-wide target" rather than requirements for each vehicle. Manufacturers can agree to pool their production quotas, so as to meet their targets on average, but there is no legal sanction for failure to meet the target. Member states are simply required to record the relevant success or failure, and manufacturers' performance is published. By contrast the Vehicles Emissions Regulation 2007 sets the "Euro 6" standards in maximum emissions that car manufacturers can have. Since the 'Euro 1' standard was introduced in 1992, standards became cleaner each 4 to 5 years, but recently stalled. Article 2 states this applies to vehicles under 2,610 kilograms, while the Heavy Vehicle Emission Regulation 2019 applies to heavier vehicles, with looser CO2 limits. Article 4 states manufacturers must 'demonstrate that all new vehicles sold, registered or put into service in the Community are type approved in accordance with this Regulation'. Article 6 requires manufacturers to 'provide unrestricted and standardised access to vehicle repair and maintenance information' should there be any non-compliance. Article 13 requires penalties imposed by member states for breach are 'effective, proportionate and dissuasive', and breaches include any 'false declarations' as well as 'use of defeat devices'.
Sources: en.wikipedia.org
== Medical contributions == Eastlack's home, Philadelphia, has become a center for FOP research with much of it concentrated at the University of Pennsylvania. With his skeleton on display, doctors and professors alike lead students to the Mütter Museum to observe the result of the rare disorder in person. Since surgeries and examinations of FOP patients exacerbate the condition, the ability to study Eastlack's skeleton has been significant for research. For example, in 2006, University of Pennsylvania's team of researchers and scientists led by Frederick Kaplan was able to distinguish the particular gene responsible for the disease, the ACVR1 gene. It is said that Eastlack's skeleton was a useful reference for this medical discovery. The International FOP Association is also granted Eastlack's skeleton for displaying and informational purposes in medical meetings and international FOP symposia, which physicians, researchers, and patients attend. For example, over 43 families were recorded to have attended a two-day symposium hosted in Philadelphia in October 1995 to listen to orthopedic surgeons and physicians discuss the details of FOP. During this symposium, Eastlack's skeleton was used as a reference. After seeing his skeleton at this event, fellow FOP patient Carol Orzel decided to also donate her body to the museum. She died in February 2018, and in February 2019, her skeleton was put on display next to his.
=== Cancer === PAHs have been linked to skin, lung, bladder, liver, and stomach cancers in well-established animal model studies. Specific compounds classified by various agencies as possible or probable human carcinogens are identified in the section "Regulation and Oversight" below.
=== Tools === Paleolithic humans made tools of stone, bone (primarily of deer), and wood. The early Paleolithic hominins, Australopithecus, were the first users of stone tools. Excavations in Gona, Ethiopia, have produced thousands of artifacts, and through radioisotopic dating and magnetostratigraphy the sites can be firmly dated to 2.6 million years ago. Evidence shows these early hominins intentionally selected raw stone with good flaking qualities and chose appropriately sized stones for their needs to produce sharp-edged tools for cutting. The earliest Paleolithic stone tool industry, the Oldowan, began around 2.6 million years ago. It produced tools such as choppers, burins, and stitching awls. It was completely replaced around 250,000 years ago by the more complex Acheulean industry, which was first conceived by Homo ergaster around 1.8–1.65 million years ago. The Acheulean implements completely vanish from the archaeological record around 100,000 years ago and were replaced by more complex Middle Paleolithic tool kits such as the Mousterian and the Aterian industries. Lower Paleolithic humans used a variety of stone tools, including hand axes and choppers. Although they appear to have used hand axes often, there is disagreement about their use. Interpretations range from cutting and chopping tools, to digging implements, to flaking cores, to the use in traps, and as a purely ritual significance, perhaps in courting behavior. William H.
=== Micro DisplayPort === Micro DisplayPort would have targeted systems that need ultra-compact connectors, such as phones, tablets and ultra-portable notebook computers. This standard would have been physically smaller than the currently available Mini DisplayPort connectors. The standard was expected to be released by Q2 2014.
Sources: en.wikipedia.org
The sequence corresponds to a fragment of a protein found in human gastric juice, so related sequences are natural. The isolated fifteen-amino-acid peptide supplied for research is produced synthetically. Whether the free fragment circulates naturally in humans has not been settled.
In most jurisdictions it is not an approved medicine and is handled as a research material. Import and sale rules differ by country, and some regulators have placed it in categories that restrict human use. Status can change, so current local rules apply.
Rodent models dominate, particularly rats with induced gastric lesions, tendon injury, or vascular disruption. These designs allow controlled comparison but differ anatomically and metabolically from humans. Results from such models are commonly cited as preliminary.
Reversed-phase HPLC separates the sample into peaks, and the main peak is expressed as a percentage of total peak area. Mass spectrometry is then used to confirm that the molecular mass matches the expected value.